Jackpot word on banner with green curtains

Getty Images

Punters winning more NFL bets are set to dent FanDuel owner Flutter’s profits

The house always wins — just a little less last quarter.

1/8/25 11:37AM

DraftKings’ biggest rival and the world’s largest online-betting company, Flutter Entertainment, is seeing a short-term hit to its bottom line from customers’ sweetest dream: gamblers are winning too much.

In a surprise trading update on Tuesday, the group (emphasis ours) detailed that:

“The 2024/2025 NFL season to date has been the most customer friendly since the launch of online sports betting with the highest rate of favorites winning in nearly 20 years.”

The “very unfavorable US sports results” are set to cost Flutter Entertainment some ~$390 million in revenue, with the company’s shares listed in London opening down 5% this morning — though the stock has since recovered all of that initial drop, with rival DraftKings also trading higher.

It’s ironic that it should be the NFL — America’s favorite league to bet on — at the heart of Flutter’s current issues, as the Dublin-headquartered group has increasingly placed its own chips on the US market, including abandoning the London Stock Exchange to move its primary listing to New York last May.

Since first combining with FanDuel seven years ago, Flutter has grown rapidly, capitalizing on the changing regulatory landscape in America, which has quickly become the company’s most important region: revenues from the US market now account for 38% of its business, up from just 12% in 2020.

Elsewhere, sports results continued a “good momentum” in the UK and Ireland region (read: punters are still losing on the English Premier League).

Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

J. Edward Moreno2/13/26

Claire Yubin Oh

The apex operator

2/13/26

SharkNinja hit an all-time high this week, as its killer growth streak continues

The viral appliance maker’s sales have more than quadrupled since 2018.

Surreal image of great white shark swimming in bedroom

Claire Yubin Oh

in this econemy?

2/12/26

Van Leeuwen, America’s fastest-growing dessert chain, is looking to expand abroad

The boutique ice cream chain is looking to open at least 300 new shops in South Korea over the next decade.

J. Edward Moreno

2/10/26

Hims built a boundary-pushing health business. Now the legal risks are catching up.

Hims is close to trading as if it never began selling GLP-1s.

Nate Becker2/7/26

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims & Hers Comms on X